Clinical Trials Logo

Clinical Trial Summary

Although ACTHAR gel is approved for the treatment of acute relapses, it is currently not widely used. Thus, we propose to conduct a small open-label proof-of-concept trial to evaluate the response to ACTHAR gel therapy in patients who have failed to make a satisfactory recovery after treatment with high dose IVMP. Documentation of the clinical course as well as any adverse events related to IVMP use will be made. The investigators propose to study the potential benefit of a 14-day course (the dose historically used since the landmark clinical trial of Rose et al1) of subcutaneous ACTHAR gel in 10 patients who have demonstrated inadequate improvement after a course of IVMP, 1000 mg daily, for 5 treatments (over a maximum of 8 days). These would be patients for whom PLEX would be considered as a treatment possibility. The primary outcome measure will be improvement in the targeted neurological deficit, as measured on the appropriate functional system score (FSS) of the EDSS.

Clinical Trial Description

This is an open-label, small, proof-of-concept study examining the safety, tolerability, and extent of recovery of a two-week course of subcutaneous Acthar Gel therapy in patients with MS relapse who have failed to make a satisfactory recovery after treatment with high dose methylprednisolone. Eligible patients will be given 80 units of Acthar for 14 days. Patients will be evaluated at baseline, at 1 week of Acthar treatment, at completion of Acthar treatment, and 1 week after completion of treatment. For those who do not undergo plasmapheresis an additional evaluation will be conducted 2 weeks after completion of treatment. Monitoring will include blood pressure determination and blood sugar determination. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT01900093
Study type Interventional
Source Icahn School of Medicine at Mount Sinai
Contact Tarah Herrmann
Phone 212-241-4264
Status Recruiting
Phase N/A
Start date July 2013
Completion date March 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Active, not recruiting NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Recruiting NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4
Recruiting NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis N/A
Recruiting NCT02232061 - Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod Phase 4
Recruiting NCT03222973 - Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) Phase 2
Recruiting NCT03122652 - Multi-center, Interventional, Phase 3, Randomized, Double-blinded Study of Treatment:Teriflunomide®, in Radiologically Isolated Syndrome Phase 3
Recruiting NCT03424733 - Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects Phase 4
Recruiting NCT03326505 - Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment Phase 1/Phase 2
Recruiting NCT02939859 - Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions N/A
Completed NCT02898974 - Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis N/A
Recruiting NCT02283671 - Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Phase 1
Active, not recruiting NCT02522962 - Innovative Physiotherapy and Coordination of Care for People With MS: a RCT and a Qualitative Study N/A
Completed NCT02571335 - Impacts of Different Training Modes (Intense Versus Ordinary) on the Immune System and Memory Functions in pwMS N/A
Not yet recruiting NCT01954823 - Use of an Electronic Diary by People With Multiple Sclerosis N/A
Recruiting NCT02408380 - Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720) N/A
Recruiting NCT02538094 - tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis N/A
Recruiting NCT02836327 - Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders N/A
Recruiting NCT02282878 - The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis N/A
Recruiting NCT02777060 - Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures N/A